冠心病血小板蛋白激酶C及其抑制剂活性的变化

Protein Kinase C and its Inhibitor Activity in Platelets from Patiens with Coronary Heart Disease

目的：探讨蛋白激酶Ｃ（ＰＫＣ）及蛋白激酶Ｃ抑制剂（ＰＫＣＩ）在冠心病发病中的作用。方法：测定４２例心绞痛患者（ＡＰ）、４１例急性心肌梗塞（ＡＭＩ）患者、４０例正常对照者（ＮＣ）血小板胞浆ＰＫＣ及ＰＫＣＩ活性，血小板胞膜ＰＫＣ活性。结果：心绞痛及急性心肌梗塞患者血小板胞浆中ＰＫＣ活性显著低于正常对照组，其中心绞痛组低于急性心肌梗塞组，心绞痛及急性心肌梗塞患者血小板胞浆中ＰＫＣＩ活性低于正常对照组，其中心绞痛组低于急性心肌梗塞组；心绞痛及急性心肌梗塞患者血小板胞膜ＰＫＣ活性显著高于正常对照组，心绞痛组高于急性心肌梗塞组。结论：ＰＫＣ可能与冠心病发病有关。

Objective:This paper was to study the relation between protein kinase C (PKC) and protein kinase C inhibitor (PKCI) in platelets from patients with coronary heart disease.Methods:We measured the activity of PKC and PKCI in cytosol of platelet and the activity of PKC in membrane of platelet from patients with angina pectoris (AP), paients with acute myocardial infarction (AMI), and normal control persons (NC), respectively.Results:The activity of PKC and PKCI in cytosol of platelet from patients with AP and AMI were lower than those of NC, respectively; the activity of PKC in membrane of platelet from patients with AP and AMI were higher than those of NC, respectively. Conclusion:PKC and PKCI might be associated with the genesis of coronary heart disease.